Loading...

Advaxis

Nasdaq:ADXS
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ADXS
Nasdaq
$76M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. The last earnings update was 109 days ago. More info.


Add to Portfolio Compare Print Invest
  • Advaxis has significant price volatility in the past 3 months.
ADXS Share Price and Events
Price Volatility
ADXS
Industry
5yr Volatility vs Market

Value

 Is Advaxis undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Advaxis. This is due to cash flow or dividend data being unavailable. The share price is $1.44.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Advaxis's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Advaxis's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:ADXS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-04-30) in USD $-2.08
NasdaqGS:ADXS Share Price ** NasdaqGS (2018-08-17) in USD $1.44
United States of America Biotechs Industry PE Ratio Median Figure of 70 Publicly-Listed Biotechs Companies 27.38x
United States of America Market PE Ratio Median Figure of 7,196 Publicly-Listed Companies 18.08x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Advaxis.

NasdaqGS:ADXS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ADXS Share Price ÷ EPS (both in USD)

= 1.44 ÷ -2.08

-0.69x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Advaxis is loss making, we can't compare its value to the US Biotechs industry average.
  • Advaxis is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Advaxis's expected growth come at a high price?
Raw Data
NasdaqGS:ADXS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.69x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
4%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 52 Publicly-Listed Biotechs Companies 1.7x
United States of America Market PEG Ratio Median Figure of 5,692 Publicly-Listed Companies 1.59x

*Line of best fit is calculated by linear regression .

NasdaqGS:ADXS PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= -0.69x ÷ 4%

-0.17x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Advaxis is loss making, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Advaxis's assets?
Raw Data
NasdaqGS:ADXS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-04-30) in USD $0.86
NasdaqGS:ADXS Share Price * NasdaqGS (2018-08-17) in USD $1.44
United States of America Biotechs Industry PB Ratio Median Figure of 565 Publicly-Listed Biotechs Companies 4.3x
United States of America Market PB Ratio Median Figure of 11,745 Publicly-Listed Companies 1.86x
NasdaqGS:ADXS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ADXS Share Price ÷ Book Value per Share (both in USD)

= 1.44 ÷ 0.86

1.67x

* Primary Listing of Advaxis.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Advaxis is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Advaxis's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Advaxis has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Advaxis expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Advaxis expected to grow at an attractive rate?
  • Unable to compare Advaxis's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Advaxis's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Advaxis's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:ADXS Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:ADXS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 4%
NasdaqGS:ADXS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 31.5%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 20.5%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 11.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 6.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:ADXS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:ADXS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-10-31 28 -64 1
2021-10-31 20 -67 1
2020-10-31 12 -68 1
2019-10-31 8 -65 2
2018-10-31 8 -60 2
NasdaqGS:ADXS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-04-30 9 -74 -90
2018-01-31 10 -75 -97
2017-10-31 12 -77 -93
2017-07-31 14 -37 -92
2017-04-30 11 -26 -76
2017-01-31 8 -18 -71
2016-10-31 4 -9 -74
2016-07-31 0 -40 -64
2016-04-30 0 -32 -62
2016-01-31 0 -27 -60
2015-10-31 -24 -47
2015-07-31 0 -19 -38

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Advaxis is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Advaxis's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:ADXS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Advaxis Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:ADXS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-10-31 -0.68 -0.68 -0.68 1.00
2021-10-31 -0.71 -0.71 -0.71 1.00
2020-10-31 -0.82 -0.82 -0.82 1.00
2019-10-31 -0.90 -0.90 -0.90 1.00
2018-10-31 -1.16 -1.16 -1.16 1.00
NasdaqGS:ADXS Past Financials Data
Date (Data in USD Millions) EPS *
2018-04-30 -2.08
2018-01-31 -2.37
2017-10-31 -2.31
2017-07-31 -2.29
2017-04-30 -1.96
2017-01-31 -1.91
2016-10-31 -2.08
2016-07-31 -1.91
2016-04-30 -1.87
2016-01-31 -1.93
2015-10-31 -1.68
2015-07-31 -1.53

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Advaxis will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Advaxis's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Advaxis has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Advaxis performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Advaxis's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Advaxis does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Advaxis's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Advaxis's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Advaxis's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Advaxis Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:ADXS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-04-30 8.62 -89.79 33.34 69.32
2018-01-31 10.30 -96.85 36.86 74.86
2017-10-31 12.03 -93.44 38.66 71.59
2017-07-31 14.01 -91.88 44.49 64.45
2017-04-30 10.96 -75.74 32.85 56.82
2017-01-31 7.54 -70.79 31.90 49.36
2016-10-31 3.99 -73.56 31.71 48.77
2016-07-31 0.25 -64.43 27.55 39.24
2016-04-30 0.25 -61.51 27.41 36.44
2016-01-31 0.25 -59.84 28.23 33.86
2015-10-31 -47.03 24.24 24.43
2015-07-31 0.00 -37.70 19.00 19.73
2015-04-30 0.00 -29.91 15.70 15.40
2015-01-31 1.00 -18.37 10.10 10.76
2014-10-31 1.00 -16.53 11.18 8.86
2014-07-31 1.00 -20.69 12.21 7.32
2014-04-30 1.00 -16.69 10.95 5.63
2014-01-31 -19.84 12.27 6.20
2013-10-31 -20.54 9.07 5.62
2013-07-31 -15.31 7.69 5.30
2013-04-30 -16.82 8.21 5.31
2013-01-31 -14.15 5.86 5.41
2012-10-31 -12.81 5.69 6.65
2012-07-31 -13.70 5.66 7.45
2012-04-30 -6.95 5.04 8.07
2012-01-31 -13.97 4.99 8.30
2011-10-31 -9.65 4.94 8.08

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Advaxis has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Advaxis has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Advaxis improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Advaxis's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Advaxis has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Advaxis's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Advaxis's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Advaxis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Advaxis's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Advaxis's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Advaxis has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Advaxis Company Filings, last reported 3 months ago.

NasdaqGS:ADXS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-04-30 45.46 0.00 57.87
2018-01-31 39.27 0.00 58.37
2017-10-31 54.26 0.00 70.30
2017-07-31 74.36 0.00 89.41
2017-04-30 91.88 0.00 115.32
2017-01-31 107.37 0.00 136.86
2016-10-31 119.30 0.00 152.09
2016-07-31 83.60 0.00 78.72
2016-04-30 95.19 0.00 94.58
2016-01-31 105.18 0.03 106.80
2015-10-31 115.60 0.03 112.16
2015-07-31 97.53 0.03 97.14
2015-04-30 47.37 0.03 45.94
2015-01-31 31.40 0.06 30.58
2014-10-31 20.63 0.06 17.61
2014-07-31 23.27 0.06 22.15
2014-04-30 27.50 0.06 27.57
2014-01-31 14.86 0.23 15.96
2013-10-31 18.00 0.23 20.55
2013-07-31 -6.73 3.57 0.00
2013-04-30 -6.29 3.34 1.01
2013-01-31 -7.86 3.33 0.00
2012-10-31 -5.96 2.82 0.00
2012-07-31 -5.00 1.73 0.01
2012-04-30 -11.80 4.61 0.01
2012-01-31 -11.06 3.71 0.59
2011-10-31 -12.57 5.12 1.10
  • Advaxis has no debt.
  • Advaxis currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Advaxis has sufficient cash runway for 1.2 years based on current financial obligations.
  • Advaxis has sufficient cash runway for 1.6 years if financial obligations continue to grow at historical rates of 69.7% each year.
X
Financial health checks
We assess Advaxis's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Advaxis has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Advaxis's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Advaxis dividends.
If you bought $2,000 of Advaxis shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Advaxis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Advaxis's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:ADXS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
United States of America Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 17 Stocks 1.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 5595 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:ADXS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-10-31
2021-10-31
2020-10-31
2019-10-31
2018-10-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Advaxis has not reported any payouts.
  • Unable to verify if Advaxis's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Advaxis's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Advaxis has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Advaxis's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Advaxis afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Advaxis has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Advaxis's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ken Berlin, image provided by Google.
Ken Berlin
AGE 54
TENURE AS CEO 0.3 years
CEO Bio

Mr. Kenneth A. Berlin, also known as Ken, J.D., serves as President, Chief Executive Officer and Director of Advaxis, Inc. since April 23, 2018. He served as the Chief Executive Officer and President of Rosetta Genomics, Ltd. since November 2, 2009 until April 18, 2018. Mr. Berlin served as a Worldwide General Manager at cellular and molecular cancer diagnostics developer Veridex LLC, a Johnson & Johnson company. Mr. Berlin began his career as an attorney at Simpson Thacher & Bartlett in New York City. Mr. Berlin joined Johnson & Johnson in 1994 and served as corporate counsel for six years. He led and participated on the legal team that oversaw several mergers, acquisitions, divestitures and commercial transactions across Johnson & Johnson. He then held positions of increasing responsibility within Johnson & Johnson and a number of its subsidiary companies. From 2001 to 2004, Mr. Berlin served as Vice President of licensing and new business development in the pharmaceuticals group and from 2004 to 2007 served as Worldwide Vice President, franchise development Ortho-Clinical Diagnostics. He served as a Director of Rosetta Genomics Ltd. from December 2009 to March 2011. He has received several awards including the 2004 Pharmaceutical Achievement Award--Licensing Deal of the Year Finalist. He is a member of the board of directors of the Central and South Jersey Chapter of Susan G. Komen for the Cure. During Mr. Berlin's tenure, Veridex received numerous awards including recognition from the Cleveland Clinic and Prix Galien for the use of its innovative CellSearch(R) technology in the fight against cancer. Mr. Berlin holds an A.B. Degree from Princeton University and a J.D. from the University of California Los Angeles School of Law.

CEO Compensation
  • Insufficient data for Ken to compare compensation growth.
  • Insufficient data for Ken to establish whether their compensation is reasonable for a company of this size and profit level.
Management Team Tenure

Average tenure and age of the Advaxis management team in years:

1.4
Average Tenure
57
Average Age
  • The average tenure for the Advaxis management team is less than 2 years, this suggests a new team.
Management Team

Robert Petit

TITLE
Executive VP & Chief Scientific Officer
COMPENSATION
$2M
AGE
58
TENURE
5.3 yrs

Tony Lombardo

TITLE
Executive Officer
COMPENSATION
$1M
AGE
69
TENURE
0.3 yrs

Ken Berlin

TITLE
President
AGE
54
TENURE
0.3 yrs

Molly Henderson

TITLE
Executive VP & CFO
AGE
47
TENURE
0.2 yrs

Mayo Pujols

TITLE
Senior Vice President of Technical Operations
TENURE
1.6 yrs

Noelle Heber

TITLE
Senior Director of Corporate Communications & Government Affairs

Thomas Hare

TITLE
Senior Vice President of Product Development
TENURE
1.6 yrs

Andres Gutierrez

TITLE
Executive VP & Chief Medical Officer
AGE
57
TENURE
0.3 yrs

Ranya Dajani

TITLE
Vice President of Business Development
TENURE
1.6 yrs

Al Blunt

TITLE
Vice President of Medical
TENURE
1.4 yrs
Board of Directors Tenure

Average tenure and age of the Advaxis board of directors in years:

3.8
Average Tenure
56
Average Age
  • The tenure for the Advaxis board of directors is about average.
Board of Directors

David Sidransky

TITLE
Chairman
COMPENSATION
$299K
AGE
58
TENURE
3.3 yrs

Ken Berlin

TITLE
President
AGE
54
TENURE
0.3 yrs

Jim Patton

TITLE
Vice Chairman of the Board
COMPENSATION
$264K
AGE
60

Richard Berman

TITLE
Independent Director
COMPENSATION
$231K
AGE
75
TENURE
12.9 yrs

Samir Khleif

TITLE
Independent Director
COMPENSATION
$227K
AGE
54
TENURE
3.8 yrs

Roni Appel

TITLE
Independent Director
COMPENSATION
$217K
AGE
51
TENURE
13.8 yrs

Antoni Ribas

TITLE
Member of Scientific Advisory Board

Jedd Wolchok

TITLE
Member of Scientific Advisory Board

Nancy Freitag

TITLE
Member of Scientific Advisory Board

Marc Lecuit

TITLE
Member of Scientific Advisory Board
Recent Insider Trading
  • No 3 month insider trading information.
Who owns this company?
X
Management checks
We assess Advaxis's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap and profit (greater than 0.5% of the company's profit + 0.03% of market cap)? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Advaxis has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

Future Outlook Of The Healthcare Industry And Advaxis Inc (NASDAQ:ADXS)

is a healthcare company operating in an industry, … The growth in development of new drugs for unmet needs, as well as the ongoing and increasing need for biotech drugs as Baby Boomer generation continues to age, are growth drivers for the positive outlook in the biotech industry over the long term … a positive double-digit growth

Simply Wall St -

What’s Ahead For Advaxis Inc (NASDAQ:ADXS)?

Not surprisingly, this rate is more than double the growth rate of the US stock market as a whole. … However, the future seems brighter, as analysts expect an industry-beating growth rate of 24.42% in the upcoming year. … If Advaxis has been on your watchlist for a while, now may be the time to enter into the stock, if you like its growth prospects and are not highly concentrated in the biotech industry.

Simply Wall St -

Advaxis Inc (NASDAQ:ADXS): How Does It Impact Your Portfolio?

ADXS, with its market capitalisation of US$112.65M, is a small-cap stock, which generally have higher beta than similar companies of larger size. … An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive. … Thus, we can expect ADXS to be more stable in the face of market movements, relative to its peers of similar size but with a higher portion of fixed assets on their books.

Simply Wall St -

Who Are The Largest Shareholders In Advaxis Inc (NASDAQ:ADXS)?

NasdaqGS:ADXS Insider_trading Mar 9th 18 General Public Ownership A substantial ownership of 58.47% in ADXS is held by the general public. … Public Company Ownership Another group of owners that a potential investor in ADXS should consider are other public companies, with a stake of 5.95%. … With this size of ownership in ADXS, this ownership class can affect the company's business strategy.

Simply Wall St -

Advaxis Inc's (NASDAQ:ADXS) Earnings Declined -27.03%, But How Did It Fare Against The Industry?

For investors with a long-term horizon, assessing earnings trend over time and against industry benchmarks is more valuable than looking at a single earnings announcement in one point in time. … See our latest analysis for Advaxis Was ADXS's recent earnings decline worse than the long-term trend and the industry? … For the most up-to-date info, I use the ‘latest twelve-month’ data, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data.

Simply Wall St -

Advaxis Inc's (NASDAQ:ADXS) Shift From Loss To Profit

Check out our latest analysis for Advaxis ADXS is bordering on breakeven, according to analysts. … How fast will ADXS have to grow each year in order to reach the breakeven point by 2022? … Next Steps: There are too many aspects of ADXS to cover in one brief article, but the key fundamentals for the company can all be found in one place – ADXS’s company page on Simply Wall St.

Simply Wall St -

Advaxis Inc (NASDAQ:ADXS): Are Analysts Right About The Drop In Earnings?

However, this is still an improvement on its past 5-year earnings growth rate of -37.04%, on average. … I've plotted out each year's earnings expectations and inserted a line of best fit to calculate an annual growth rate from the slope in order to understand the overall trajectory of ADXS's earnings growth over these next few years. … NasdaqGS:ADXS Future Profit Jan 5th 18 By 2021, ADXS's earnings should reach $-82.7M, from current levels of $-93.4M, resulting in an annual growth rate of 33.24%.

Simply Wall St -

Advaxis Inc (NASDAQ:ADXS): Will The Growth Last?

Advaxis Inc's (NASDAQ:ADXS) latest earnings update in October 2017 showed company earnings became less negative compared to the previous year's level - great news for investors Today I want to provide a brief commentary on how market analysts predict Advaxis's earnings growth trajectory over the next few years and whether the future looks brighter. … See our latest analysis for Advaxis Market analysts' consensus outlook for this coming year seems pessimistic, with earnings becoming even more negative, generating $-115.0M in 2018. … NasdaqGS:ADXS Future Profit Dec 28th 17 Even though it is useful to be aware of the growth each year relative to today’s value, it may be more beneficial estimating the rate at which the earnings are moving on average every year.

Simply Wall St -

Has Advaxis Inc (NASDAQ:ADXS) Got Enough Cash To Cover Its Short-Term Obligations?

The direct benefit for Advaxis Inc (NASDAQ:ADXS), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … See our latest analysis for Advaxis Is ADXS right in choosing financial flexibility over lower cost of capital? … Choosing financial flexibility over capital returns make sense if ADXS is a high-growth company.

Simply Wall St -

Is Now The Time To Bet On The Healthcare Sector And Advaxis Inc (ADXS)?

The demand for new drug development to meet new or persistent chronic illnesses, as well as the ongoing need for biotech drugs as Baby Boomers continue to age, are growth drivers for the optimistic outlook for the biotech industry in the long run. … In the previous year, the industry saw growth of 8.45%, though still underperforming the wider US stock market. … ADXS lags the pack with its negative growth rate of -20.11% over the past year, which indicates the company will be growing at a slower pace than its biotech peers.

Simply Wall St -

Company Info

Map
Description

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers. The company is also developing Axalimogene filolisbac for the treatment of anal cancer; ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is designed to target the prostate specific antigen associated with prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient’s immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with Bristol-Myers Squibb Company; Amgen Inc.; Sellas Life Science Group; Merck & Co., Inc.; MedImmune/AstraZeneca PLC; Especificos Stendhal SA de CV; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.

Details
Name: Advaxis, Inc.
ADXS
Exchange: NasdaqGS
Founded: 2002
$75,774,945
52,621,490
Website: http://www.advaxis.com
Address: Advaxis, Inc.
305 College Road East,
Princeton,
New Jersey, 08540,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ADXS Common Shares Nasdaq Global Select US USD 28. Jul 2005
Number of employees
Current staff
Staff numbers
108
Advaxis employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/08/17 21:19
End of day share price update: 2018/08/17 00:00
Last estimates confirmation: 2018/06/13
Last earnings update: 2018/04/30
Last annual earnings update: 2017/10/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.